|
25 Companies |
|
28 Products |
|
28 Products |
|
44 Mechanisms of Action |
|
0 Trials |
|
80 News |
|
| «12 |
- BI2536 / Boehringer Ingelheim
Enrollment change, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 19, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=185 --> 76
- |||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 18, 2013
P2, N=148, Completed, Sponsor: GlaxoSmithKline
N=185 --> 76 Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 12, 2013
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial termination, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2013
P2b, N=370, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III.
- Enrollment change: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. N=180 --> 0
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (clinicaltrials.gov) - Mar 19, 2013
P2, N=52, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=180 --> 0 N=102 --> 52
- cyclophosphamide / Generic mfg.
Enrollment open, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 12, 2013
P1, N=7, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=102 --> 52 Suspended --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Mar 3, 2013
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- celecoxib oral / Generic mfg.
Enrollment change, Surgery: Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery (clinicaltrials.gov) - Feb 17, 2013
P1, N=3, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Recruiting N=24 --> 3
- Leukine (sargramostim) / Partner Therap
Trial termination: Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 12, 2013
P1, N=0, Terminated, Sponsor: Columbia University
N=24 --> 3 Active, not recruiting --> Terminated; Departure of PI
- sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma (clinicaltrials.gov) - Dec 12, 2012
P2, N=147, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Departure of PI Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=45 --> 24
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=24, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=45 --> 24 Recruiting --> Completed
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed N=44 --> 132
- gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=48, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=44 --> 132 Active, not recruiting --> Completed
- pegylated liposomal doxorubicin / Generic mfg., ifosfamide / Generic mfg.
Trial completion, Combination therapy, Metastases: Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P1, N=28, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- imatinib / Generic mfg.
Trial completion, Metastases: STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=91, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases: Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=132, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Sep 5, 2012
P=N/A, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- brostallicin (PNU-166196) / SOBI
Trial completion, Metastases: Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=64, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion, Metastases: Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 16, 2012
P2, N=39, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-EORTC-62933: Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 9, 2012
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
New P2 trial, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 6, 2012
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- |||| cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma (clinicaltrials.gov) - May 7, 2012
P2, N=111, Completed, Sponsor: ImClone LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- yttrium Y 90 tabituximab barzuxetan (OTSA101-DTPA-90Y) / OncoTherapy
Enrollment open: SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (clinicaltrials.gov) - Apr 2, 2012
P1, N=18, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Clinical: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 18, 2012
P3, N=780, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
New P1 trial, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 20, 2011
P1, N=7, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | yttrium Y 90 tabituximab barzuxetan (OTSA101-DTPA-90Y) / OncoTherapy
New P1 trial: SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (clinicaltrials.gov) - Nov 8, 2011
P1, N=18, Recruiting, Sponsor: Centre Leon Berard